← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Bisphosphonates
zoledronic acid
M05BA08
Forms & Strengths
- Intravenous solution: 4 mg/5 mL
- Intravenous infusion: 5 mg/100 mL
Adult Dosing
- Osteoporosis treatment: 5 mg IV once yearly
- Osteoporosis prevention: 5 mg IV once every 2 years
- Paget's disease: 5 mg IV single infusion
- Hypercalcemia of malignancy: 4 mg IV single infusion, may repeat after 7 days
- Cancer-induced bone metastases: 4 mg IV every 3-4 weeks
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
- Off-label severe osteogenesis imperfecta: 0.025-0.05 mg/kg IV every 3-6 months (institutional protocols vary)
Indications
- Treatment and prevention of postmenopausal osteoporosis
- Treatment to increase bone mass in men with osteoporosis
- Treatment and prevention of glucocorticoid-induced osteoporosis
- Treatment of Paget's disease of bone
- Treatment of hypercalcemia of malignancy
- Prevention of skeletal-related events in patients with multiple myeloma and bone metastases from solid tumors
Mechanism of Action
- Potent nitrogen-containing bisphosphonate
- Binds to hydroxyapatite crystals in bone, inhibiting osteoclast activity
- Reduces bone resorption and bone turnover
- Induces osteoclast apoptosis via inhibition of the farnesyl pyrophosphate synthase pathway
Contraindications
- Hypersensitivity to zoledronic acid or other bisphosphonates
- Hypocalcemia
- Severe renal impairment (CrCl < 35 mL/min for osteoporosis indications)
- Pregnancy and lactation
Adverse Reactions
- Acute phase reaction (fever, myalgia, arthralgia, headache, fatigue within 3 days of infusion)
- Transient hypocalcemia
- Nausea, vomiting, diarrhea
- Flu-like illness
- Osteonecrosis of the jaw (ONJ)
- Atypical femoral fractures
- Renal function impairment / acute kidney injury
Drug Interactions
- Aminoglycosides: May increase risk of severe hypocalcemia and prolonged hypocalcemia
- Loop diuretics: Increased risk of hypocalcemia and nephrotoxicity
- Nephrotoxic drugs (e.g., NSAIDs, cisplatin): Increased risk of renal impairment
Curated Content: Needs Vetting Before Put to Clinical Use